Lyngbouilloside and the related macrolides lyngbyaloside, lyngbyaloside B and lyngbyaloside C have attracted a lot of attention over the past decade due to their intriguing architecture, their natural scarcity and their potential biological activities. This review aims to showcase the various strategies that have been used to access these natural products.
Among the variety of marine cyanobacteria, Lyngbya bouillonii has emerged as an exceptional source of new natural products, which include the linear tetrapeptide lyngbyapeptin [2] , the three macrolides: laingolide, laingolide A and madangolide [3] and the rather uncommon glycosidic macrolides lyngbouilloside, 1 [4] , lyngbyaloside (2) [5, 6] , lyngbyaloside B (3) [6, 7] and lyngbyaloside C (4) [6] (Figure 1 ). Over the past 10 years, many efforts have been dedicated to the synthesis of these last four macrolides by various groups around the world; we report here the results of their endeavours. [8] off the North Coast of Papua New Guinea, lyngbouilloside (1) is the third glycosidic macrolide to be isolated from cyanobacteria. Despite the relative and absolute configuration of both the sugar and the aglycon unit, which still remain unknown, the gross structure of lyngbouilloside was elucidated after exhaustive spectroscopic analysis and chemical derivatizations. Hence, while HRMS analysis indicated a molecular formula of C 31 H 52 O 10 suggesting the presence of six degrees of unsaturation, 13 C NMR and UV analysis allowed to establish the presence of a conjugated diene system and a carbonyl moiety. This initial observation was eventually comforted by the IR data, which, in addition to the carbonyl moiety, also revealed the presence of hydroxyl groups. Interestingly, NMR analysis of the corresponding acetylated lyngbouilloside also helped determine the structure of the backbone core. Indeed, while the planar structure of the natural product was established through 1D and 2D NMR analysis, the nature of the sugar moiety and the relative configuration of its stereogenic centers were assigned by comparing the NMR data with the ones pertaining to the sugar moiety in the Dolabella auricularia metabolite auriside A (7) [9] . Additional NMR experiments, in particular ROESY correlations between H-5 and H-7, and H-7 and H-10 established the relative configuration of the centers in the aglycon portion of lyngbouilloside as (3S,5R,7S,10R,11S,13R) while correlations in the 1 H-1 H COSY and HMBC spectral data confirmed the presence of a 2,4-di-O-methylrhamnopyranoside unit and a hemiketal pyran. Finally, homonuclear coupling constant analysis combined to a ROESY correlation from H-1′ to OMe-2′ identified the sugar as the -anomer.
The extreme scarcity of lyngbouilloside unfortunately did not allow to establish a complete biological profile of the natural product. However, Gerwick et al. were able to show that it was moderately cytotoxic against neuro-2a neuroblastoma cells with an IC 50 = 17 M. Nonetheless, the significant cytoxicity displayed by the structurally related 14-membered macrolides, callipeltoside A, (5) phorbaside A (6), auriside A (7) and dolastatin 19 (8) (Figure 2 ), suggests a promising cytotoxic activity. Since its isolation in 2002, a few groups have tried to complete the synthesis of this 14-membered ring glycosidic macrolide. However, despite several approaches, there has been no total synthesis of lyngbouilloside reported so far.
In 2009, Ley et al. [10] reported their initial efforts towards the synthesis of the macrocyclic core of lyngbouilloside. The key steps of their strategy included a RCM to build the macrolactone [11] through the C8-C9 bond, an enolate-lactone coupling to install the C3 substituent on the pyran ring, a double conjugate addition of a propane-1,3-dithiol onto a conjugated ester followed by an in situ cyclization to generate the desired lactone and a stereoselective Brown crotylation to control the C10 and C11 stereogenic centers (Scheme 1) [ The synthesis of the C3-C8 fragment of lyngbouilloside began from the known ynone 9, which was prepared in two steps starting from (S)-glycidol [13] via a double conjugate addition with propane-1,3dithiol followed by an in situ cyclization. The resulting lactone was then reduced with DIBAL-H to the corresponding hemiketal 10, which was obtained as a mixture of two diastereomers (dr = 1.5:1) in 87% overall yield. Deprotonation of the resulting -lactol with KHMDS in the presence of 18-crown-6 [14] afforded the corresponding alkoxide which underwent a highly diastereoselective methylation to ketal 11. A few subsequent steps allowed to set the terminal olefin and convert the dithiol moiety to the corresponding ketone 12, while reduction with sodium borohydride introduced the C5 stereogenic center and generated 13 as a single diastereomer in 99% yield. A final PMB-protection/ hydrolysis/oxidation sequence eventually provided the desired lactone 14 in 46% yield (Scheme 2). The C9-C13 fragment 20 on the other hand, was prepared via a regioselective opening of the optically active epoxide 15 with allyl magnesium chloride followed by a sequential ozonolysis/NaBH 4mediated reduction of the resulting mono-protected 1,3-diol 16 to afford diol 17, which was further converted to the corresponding aldehyde 18. The latter was then engaged in a Brown type crotylboration to afford anti-homoallylic alcohol 19 (dr > 19:1), which was eventually converted to the desired C9-C13 fragment 20 after several protecting group manipulations (Scheme 3). With effective routes to both the C3-C8 and C9-C13 fragments of lyngbouilloside in hand, Ley et al. then turned their attention to their coupling (Scheme 4). To that effect, lactone 14 was added to the lithium enolate derived from 20 to afford the corresponding lactol which was subsequently converted to the acetal and ringclosed using the Hoveyda-Grubbs' second-generation catalyst in the presence of 1,4-benzoquinone [11] . The resulting macrocycle 21 was finally treated with TBAF to remove the TBS protecting group, while a hydrogenation followed by a mild acid hydrolysis provided the desired macrolactone 22 in 46% yield over four steps. Roughly at the same time as Ley et al., Arseniyadis, Cossy and co-workers [15] also got involved in the total synthesis of lyngbouilloside. Their initial strategy involved a glycosylation to introduce the hexapyranoside moiety, an intramolecular acylketene trapping macrolactonization [16] to build the macrolactone core, a cross-metathesis to join the C1-C8 and C9-C13 fragments together, a highly enantio-and diastereoselective crotyltitanation and a vinylogous aldol [16] to control the C5, C10 and C11 stereogenic centers (Scheme 5).
OTBS
Their synthesis started with the preparation of the two crossmetathesis coupling partners 28 and 30 (Scheme 6). The former was prepared via a vinylogous aldol between 4-pentenal (25) and the silyl dienol ether derived from 2,2,6-trimethyl-4H-1,3-dioxin-4-one (26) [17] to afford the corresponding alcohol 27 as a racemic mixture of enantiomers which were separated by chiral preparative HPLC. The required (R)-enantiomer [18], was then engaged in two concomitant allylic oxidations to afford the targeted enone 28 in 17% overall yield.
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The synthesis of the second cross-metathesis coupling partner 30 first implied the conversion of (S)-citramalic acid (24) to the corresponding acetal 29 through the esterification of the two carboxylic acid moieties followed by a LiAlH 4 -mediated reduction and a chemoselective protection of the resulting triol. The remaining free primary alcohol was then oxidized to the corresponding aldehyde using PCC, and engaged in a highly enantio-and diastereoseletive crotyltitanation using Duthaler-Hafner's reagent, (S,S)-[Ti]-III [19] . The resulting homoallylic alcohol was finally protected as a PMB ether to afford the desired olefinic coupling partner 30 in six steps and 51% overall yield. The two subunits 28 and 30 were then engaged in a secondgeneration Hoveyda-Grubbs catalyst-mediated cross-metathesis and the resulting enone was directly reduced to the saturated ketone 31 via a catalytic hydrogenation. The latter was finally converted to the macrolactone precursor 33 via a five-step sequence involving a 1,3-anti reduction using tetramethylammonium triacetoxyborohydride [20] , the protection of the hydroxyl groups as PMB ethers [21] , the removal of the acetal under mild acidic conditions, the oxidation of the newly released primary alcohol and the olefination of the resulting aldehyde under standard Wittig conditions. Unfortunately, the Wittig olefination appeared to be very low yielding resulting in only small amounts of the macrolactone precursor thus forcing the authors to modify their synthesis.
After considering the successes and the downfalls of their initial approach, Cossy et al. decided to slightly change their strategy [23] . Hence, while the glycosylation, the macrolactonization via intramolecular acylketene trapping and the cross-metathesis were reconducted, the sequential hydroboration/Suzuki coupling to introduce the (E,E)-diene side chain was replaced by a three-step sequence featuring a Sonogashira coupling, a hydrosilylation and a protodesilylation which required the introduction of the alkyne moiety in the early stages of the synthesis (Scheme 7). Moreover, an asymmetric version of the vinylogous aldol was foreseen to control the C5 stereogenic center while preventing the unnecessary waste of half of their material. Finally, the control of the quaternary stereogenic center at C13 was envisioned through a Sharpless dihydroxylation of commercially available 3-methylbut-3-ol (35) . conditions, the expected aldol product (R)-27 was obtained in 86% ee albeit with a moderate 40% yield. To complete the synthesis, the latter was then treated with SeO 2 and t-BuOOH to afford the corresponding diol, which was subsequently engaged in a MnO 2 -mediated oxidation to provide the desired enone 28 in 42% overall yield.
The synthesis of the C9-C17 fragment, on the other hand, began with the protection of 3-methylbut-3-enol (35) as a p-methoxyphenyl ether using diisopropylazodicarboxylate and triphenylphosphine in refluxing THF [26] . The latter was then engaged in a Sharpless dihydroxylation [27] with AD-mix- to afford diol 37 in quantitative yield and 94% ee (Scheme 9) [28] . The primary alcohol was then converted to the corresponding mesylate which was subsequently treated with K 2 CO 3 in MeOH to afford epoxide 38 [29] in 88% yield over two steps. Ring-opening of the epoxide with allenyl magnesium bromide [30] , followed by protection of the terminal alkyne and removal of the PMP protecting group eventually afforded diol 41, which was engaged in a TEMPO-mediated oxidation to provide the corresponding aldehyde in 75% yield. The latter was then crotylated in a highly stereoselective fashion using the chiral crotyltitanium reagent (S,S)-[Ti]-III to afford homoallylic alcohol 42 as a single diastereoisomer in 88% yield. Finally, in order to prevent any concomitant oxo-Michael addition that could occur during the cross-metathesis step due to the presence of the free hydroxyl group [31] , the diol was protected as a p-methoxybenzylidene acetal. With the syntheses of the C1-C8 and C9-C17 subunits secured, the construction of the macrolactone precursor was then undertaken (Scheme 10). The two olefinic coupling partners 28 and 43 were thus subjected to a second generation Hoveyda-Grubbs catalyst (20 mol %)-mediated cross-metathesis in refluxing CH 2 Cl 2 to furnish enone 44 in 78% yield. The ,-unsaturated ketone was then reduced chemoselectively using an in situ generated hydridocuprate [32] to afford the saturated ketone 45 which was treated with DDQ in a CH 2 Cl 2 /pH 7.2 phosphate buffer mixture in order to oxidatively open the cyclic PMP acetal in a regioselective fashion [33] . The resulting -hydroxy ketone 46 was then diastereoselectively reduced using Evans protocol [(Me) 4 NBH(OAc) 3 , MeCN, AcOH] to afford the corresponding triol 47, which was finally protected as a bis-triethylsilyl ether.
In order to build the 14-membered ring macrocycle, the macrolactone precursor 48 was subjected to thermolysis conditions in order to trigger the formation of the highly reactive acylketene intermediate 49 which would in turn be instantaneously trapped intramolecularly by the tertiary alcohol to form the corresponding -keto lactone 50 (Scheme 11) [22, 34] . As expected, refluxing dioxinone 48 in toluene under dilute conditions (c = 10 -4 M) and treating the crude reaction mixture with p-TsOH, led to the formation of the macrolactone with concomitant loss of both TES protecting groups. The introduction of the side chain then began with the removal of the TIPS protecting group using AgF followed by a mild acidic work-up [35] . The corresponding terminal alkyne was subsequently engaged in a PdCl 2 (PPh 3 ) 2 /CuI-catalyzed Scheme 11: Synthesis of the macrolactone core and introduction of the side chain.
Sonogashira coupling [36] with (E)-1-iodobut-1-ene (52) [37] to afford the desired enyne 53 in 48% yield. At this stage, the cleavage of the p-methoxybenzoate moiety was explored and proved to be particularly troublesome as none of the conditions tested [38] resulted in the isolation of the fully deprotected lyngbouilloside precursor.
Encouraged by the overall proof-of-concept, Cossy et al. pursued yet an ultimate approach based on a different protecting group strategy and on the installation of half of the side chain early in the synthesis thus avoiding the delicate late-stage aldehyde methylenation.
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The synthesis of the macrolactone core of lyngbouilloside thus began with the suitable protection of diol 42 (Scheme 12). The latter was therefore treated with an excess of TESOTf to quantitatively afford the bis-TES ether 56, which was then subjected to the same second generation Hoveyda-Grubbs catalyst-mediated CM with enone 28 to afford the desired coupled product 57 in 81% yield. The resulting enone was then reduced to the corresponding saturated ketone using Stryker's reagent, while a highly diastereoselective anti-reduction of the -hydroxy ketone 58 under Evans' conditions [(Me) 4 NBH(OAc) 3 , MeCN, AcOH] afforded the desired 1,3-anti diol 59 as a unique diastereomer. The TES protecting groups were eventually removed under mild conditions using a catalytic amount of FeCl 3 ·6H 2 O in methanol, and the resulting secondary alcohols were re-protected as TES ethers to afford the key macrolide precursor 60 in 60% yield over two steps. With dioxinone 60 in hand, the stage was set for the sequential thermal macrolactonization/pyran hemiketal formation which would ultimately afford the lyngbouilloside aglycon precursor. Interestingly, thermolysis of dioxinone 60 in rigorously anhydrous refluxing toluene (c = 10 -4 M) and subsequent treatment with HF·Py in a THF/Py mixture afforded the desired fully TES-deprotected macrolactone 61 in 62% overall yield. In order to complete the synthesis, the latter was then treated with AgF to afford the corresponding terminal alkyne which was engaged in the same PdCl 2 (PPh 3 ) 2 /CuI-catalyzed Sonogashira coupling as previously.
The resulting enyne was finally subjected to the approved one-pot hydrosilylation/protodesilylation sequence [39] , which resulted in the isolation of lyngbouilloside aglycon 62 in 28% overall yield. Interestingly, comparison of the NMR chemical shifts of their synthetic sample with the ones reported for the natural product (Table 1) , particularly in the C9-C13 region, strongly suggested a possible misassignment, which confirmed Ley's initial observation. This hypothesis was also comforted by the fact that the 13 C NMR data of both lyngbouilloside (1) and lyngbyaloside C (4) were virtually identical within the region of the macrocycle while the proposed structures of the two natural products differ at C11. [40] . Their strategy featured a sequential CM/Wittig olefination to introduce the diene moiety and their stereoselective ether transfer method to afford the 1,3-syn-diether motif [41] (Scheme 13). As shown in Scheme 14, their synthesis began with the regioselective opening of epoxy alcohol 63 with methylmagnesium bromide followed by the protection of the resulting primary alcohol as a tert-butyldiphenylsilyl (TBDPS) ether and the introduction of the transferable naphthylmethyloxymethyl group. Activation of the alkene moiety with iodine monochloride in toluene at low temperature then initiated a stereoselective cyclization to form a transient oxonium ion which was selectively functionalized in the presence of methanol to form, after hydrolytic workup, the desired 1,3-syndiether 65 in a highly stereoselective fashion. Selective deprotection of the tertiary alcohol under mild oxidative conditions followed by the addition of allylmagnesium bromide in the presence of copper iodide and TES protection of the resulting tertiary alcohol eventually afforded terminal olefin 66 in 81% overall yield. The latter was finally subjected to a cross-metathesis with metacrolein followed by a Wittig olefination with (bromomethyl) triphenylphosphonium bromide to afford the desired C9-C19 fragment of lyngbyalosides B and C (67) as a 1:2 mixture of E/Z isomers. Lyngbouilloside and the related glycosidic macrolides lyngbyalosides B and C all possess some interesting architectural features, including a six-membered ring hemiketal, a polypropionate backbone, a side chain bearing a (E,E)-diene moiety and more than 10 stereogenic centers. However, the most characteristic and synthetically challenging feature remains the unusual tertiary methyl carbinol at C13. Given their structure and potential cytotoxicity, these natural products have been the subject of fervent synthetic endeavours. Nonetheless, more than ten years after their isolation, they still constitute a great synthetic challenge and a source of inspiration for innovation in synthetic chemistry. Their synthesis will not only enable the full stereochemical assignment and structural revision to be unambiguously made but also provide opportunities for drug discovery and development. 
